Table 2.
The potential markers of the therapeutic approaches for hepatic fibrosis.
| No. | RT (min) | Measured MS (m/z) | Adduct | Error (mDa) | Metabolites | HMDB Formula | Major Metabolic Pathway | Model | |
|---|---|---|---|---|---|---|---|---|---|
| Positive | Negative | ||||||||
| 1 | 0.95 | 132.0777 | 130.0623 | [M + H]+ | 0.9 | Creatine | C4H9N3O2 | Creatine pathway | ↓ b |
| 2 | 9.51 | 302.3050 | -- | [M + H]+ | 0.4 | Sphinganine | C18H39NO2 | Sphingolipid metabolism | ↓ c |
| 3 | 9.66 | 429.2609 | 405.2629 | [M + Na]+ | 0.2 | 3,7-Dihydroxy-12-oxocholanoic acid | C24H38O5 | Fat digestion and absorption | ↑ b |
| 4 | 9.85 | 330.2968 | 328.2448 | [M + H]+ | 3.4 | Dihydroceramide | C19H39NO3 | Sphingolipid metabolism | ↓ b |
| 5 | 10.17 | 839.5669 | 837.5508 | [M + H]+ | 2.5 | PI (18:0/16:0) | C43H83O13P | Glycerophospholipid metabolism | ↑ a |
| 6 | 10.18 | 373.2743 | -- | [M + H]+ | 0.6 | Cervonoyl ethanolamide | C24H36O3 | N-acylethanolamine biosynthesis | ↑ c |
| 7 | 10.56 | 343.2252 | 319.2274 | [M + Na]+ | 0.8 | 8-HETE | C20H32O3 | Arachidonic acid metabolism | ↓ a |
| 8 | 10.75 | 568.3404 | 612.3293 | [M + H]+ | 0.6 | LysoPC (22:6) | C30H50NO7P | Glycerophospholipid metabolism | ↑ c |
| 9 | 10.77 | 520.3398 | 518.2407 | [M + H]+ | 0.0 | LysoPC (18:2) | C26H50NO7P | Glycerophospholipid metabolism | ↑ c |
| 10 | 11.16 | 1047.7383 | 568.3617 | [2M + H]+ | 3.4 | LysoPC (0:0/18:0) | C26H54NO7P | Glycerophospholipid metabolism | ↓ a |
| 11 | 11.21 | 572.3705 | 594.3704 | [M + Na]+ | 1.8 | LysoPC (20:1) | C28H56NO7P | Glycerophospholipid metabolism | ↓ b |
| 12 | 11.25 | 560.3708 | 582.3624 | [M + Na]+ | 2.1 | LysoPC (22:0/0:0) | C27H56NO7P | Glycerophospholipid metabolism | ↓ b |
| 13 | 11.41 | 381.2979 | -- | [M + Na]+ | 0.4 | MG (0:0/18:0/0:0) | C21H42O4 | Glycerophospholipid metabolism | ↓ b |
| 14 | 12.79 | 758.5696 | 802.5616 | [M + H]+ | 0.2 | PC (18:2/16:0) | C42H80NO8P | Glycerophospholipid metabolism | ↑ b |
| 780.5525 | [M + Na]+ | 1.1 | PC (18:2/16:0) | C42H80NO8P | Glycerophospholipid metabolism | ↑ b | |||
| 15 | 13.20 | 760.5880 | 804.5800 | [M + H]+ | 2.9 | PC (18:1/16:0) | C42H82NO8P | Glycerophospholipid metabolism | ↑ c |
| 782.5699 | [M + Na]+ | 2.9 | PC (18:1/16:0) | C42H82NO8P | Glycerophospholipid metabolism | ↑ c | |||
| 16 | 12.63 | 806.5737 | 850.5636 | [M + H]+ | 4.3 | PC (20:4/18:2) | C46H80NO8P | Glycerophospholipid metabolism | ↑ c |
| 828.5555 | [M + Na]+ | 4.1 | PC (20:4/18:2) | C46H80NO9P | Glycerophospholipid metabolism | ↑ c | |||
| 17 | 13.35 | 832.5839 | 830.5999 | [M + H]+ | 1.2 | PC (22:6/18:1) | C46H84NO8P | Glycerophospholipid metabolism | ↑ a |
(Compared to the control group, a p < 0.05; b p < 0.01; c p < 0.001). --: this metabolite can not be found in the MS and MS/MS with negative mode.